- Raw materials
- Dermatological Agents
- Lithium succinate
Lithium succinate API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Lithium succinate | CAS No: 29126-50-9 | GMP-certified suppliers
A medication that is an experimental lithium compound investigated for potential dermatological applications in topical formulations requiring high-purity API sourcing.
Therapeutic categories
Product Snapshot
- Lithium succinate is an oral small molecule formulation
- It is primarily investigated for neuropsychiatric and mood disorder applications
- The compound remains in experimental status and lacks formal approval in major regulatory markets
Clinical Overview
This compound is currently considered experimental, and there is no formally established clinical indication or approved therapeutic use. As such, lithium succinate has not been assigned specific pharmacodynamic properties or a defined mechanism of action in the clinical setting. Its inclusion in dermatological categories suggests investigational use in topical or ointment formulations, but conclusive efficacy or safety data have not been established.
Regarding pharmacokinetics, absorption, distribution, metabolism, and excretion (ADME) parameters for lithium succinate have not been characterized in published literature or regulatory submissions. Without these data, a detailed assessment of its systemic exposure or metabolic pathways is not available.
From a safety and toxicity standpoint, no comprehensive profiles have been documented. The lithium moiety can carry inherent risks associated with lithium salts, such as potential systemic toxicity if absorbed, but such considerations are speculative without specific study data for lithium succinate.
No marketed pharmaceutical products or brand names featuring lithium succinate as an active pharmaceutical ingredient are currently recorded, underscoring its experimental status.
For sourcing and quality control, procurement of lithium succinate as an API requires rigorous verification of chemical purity and consistency in compliance with good manufacturing practices (GMP). Due to its experimental nature, availability may be limited to specialized suppliers, and documentation supporting identity, quality, and stability should be thoroughly evaluated to meet research or developmental standards.
Identification & chemistry
| Generic name | Lithium succinate |
|---|---|
| Molecule type | Small molecule |
| CAS | 29126-50-9 |
| UNII | MD64P82Y28 |
| DrugBank ID | DB14508 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Inositol monophosphatase 2 | Humans | |
| Inositol monophosphatase 1 | Humans | |
| Glycogen synthase kinase-3 beta | Humans |
Formulation & handling
- Lithium succinate is a small molecule suitable for oral formulations due to its high water solubility and low logP value.
- As a dicarboxylic acid derivative, it may require pH adjustment for optimal stability in aqueous solutions.
- No specific peptide or biologic handling precautions are necessary, but moisture sensitivity should be assessed during formulation.
Regulatory status
Lithium succinate is a type of Dermatological Agents
Dermatological agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the formulation of various skincare and dermatology products. These APIs are specifically designed to target and treat skin conditions, offering effective solutions for a wide range of dermatological concerns.
Dermatological agents encompass a diverse array of compounds, including corticosteroids, antifungal agents, antibacterials, retinoids, and immunomodulators. Each API within this category possesses unique properties and mechanisms of action, enabling them to address specific skin-related issues.
Corticosteroids, for instance, are potent anti-inflammatory agents commonly used in the treatment of skin conditions like eczema, psoriasis, and dermatitis. Antifungal agents, on the other hand, combat fungal infections such as athlete's foot or ringworm. Antibacterials are effective against bacterial infections, while retinoids promote skin cell turnover and treat acne and photoaging. Immunomodulators regulate the immune response, providing relief from conditions like atopic dermatitis.
The development and application of dermatological APIs involve rigorous research, clinical trials, and regulatory compliance. These APIs are typically integrated into topical creams, ointments, gels, and lotions, ensuring targeted delivery to the affected areas of the skin.
Dermatological agents play a crucial role in the management and treatment of various skin disorders. By harnessing the therapeutic properties of these APIs, pharmaceutical companies can develop innovative skincare products that cater to the diverse needs of individuals seeking effective dermatological solutions.
